Multiple Myeloma | Clinical

Rolling BLA Submission Initiated for Cilta-Cel in R/R Multiple Myeloma

December 21, 2020

Rolling submission has been initiated for a Biologics License Application, submitting data to the FDA for the potential approval of ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma.

Exploring Increase of Point Mutations Associated with High-Dose Melphalan in Multiple Myeloma

December 14, 2020

In an interview with Targeted Oncology, Mehmet Samur, PhD, discussed the investigation of high-dose melphalan following autologous stem cell transplant in patients with multiple myeloma and shared insights into how the ongoing questions can be explored in the future.

CAR T Cells Inching Toward FDA Approval in Heavily Pretreated Multiple Myeloma

December 12, 2020

In an interview with Targeted Oncology, Jesus G. Berdeja, MD, discussed a subanalysis of the KarMMA study and updated results from CARTITUDE-1, which provide insights on the use CAR T-cell therapy in heavily pretreated patients with multiple myeloma, including the elderly and frail.

Results of Selinexor Added to Pd Regimen Moves Myeloma Study on to Phase 3

December 08, 2020

The combination of selinexor plus pomalidomide and low-dose dexamethasone led to favorable responses in a cohort of patients with heavily pretreated multiple myeloma, warranting further investigation of the regimen in a phase 3 trial.

Higher Dosing Schedules of Panobinostat Plus Subcutaneous Bortezomib Triplet Appears Promising in Relapsed/Refractory Myeloma

December 07, 2020

A 20-mg 3-times-weekly or twice-weekly dosing schedule of panobinostat combined with subcutaneous bortezomib plus dexamethasone induced durable responses as treatment of patients with relapsed or refractory multiple myeloma and demonstrated an acceptable safety profile in the phase 2 PANORAMA 3 study.

Progression-Free Survival Improved With All-Oral Ixazomib Triplet in Newly-Diagnosed Transplant-Ineligible Myeloma

December 07, 2020

Ixazomib in combination with lenalidomide plus dexamethasone achieved a clinically meaningful improvement of 13.5 months in the median progression-free survival as treatment of elderly patients with transplant-ineligible newly diagnosed multiple myeloma.

Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma

December 07, 2020

The combination of daratumumab with lenalidomide, bortezomib, and dexamethasone followed by maintenance therapy with daratumumab and lenalidomide improved response rates and depth of response rates with statistically significance as treatment of patients with transplant-eligible newly diagnosed multiple myeloma.